Our Science

While we and other companies work to build a better CAR T-cell, we are also developing new ways to use CAR T science to work in concert with the human immune system to detect and kill cancer cells. Cell BT is focused on innovations that will benefit the entire field of CAR T-cell therapy, making it safer and more affordable for patients.

Solving the Solid Tumor CAR T Problem

While many are discouraged by CAR T-cell therapy’s lack of success treating solid tumors, Cell BT sees a bright light of hope.

Our solid tumor programs are designed to overcome the main obstacles to CAR T success: 

CAR T-cells lose most of their therapeutic effectiveness during the long transit time from the injection site to a deep-seated tumor.
Solid tumor cells are constantly mutating, so CAR T-cells must be engineered to target more than one antigen.
The toxic solid tumor microenvironment can “turn off” the CAR T-cell when it gets there.

Advancing Hematological CAR T Therapy

Our lead hematological program is based on a powerful combination of a unique platform and a novel target. Cell BT is leading IND-enabling studies for phase one clinical trial readiness.

We expect human trials to confirm this to be a major advance that offers:

Greatly improved efficacy
Significantly lower dose
Reduced side effects

*huLym-1-B-DAP showed rapid onset and persistence at a 60% lower dose

Working in concert with the Immune System to Cure Cancer

We’re seeing new ways CAR T-cells can engage the patient’s own immune system to synergistically target and destroy tumors. This immune system interaction or “upgrade” confers immunological memory to prevent tumors from returning permanently.  This synergy also can enhance tumor recognition which is important for preventing the outgrowth and spread of antigen negative lesions.  

Working in Concert with the Immune System to Cure Cancer

We’re seeing new ways CAR T-cells can engage the patient’s own immune system to synergistically target and destroy tumors. This immune system interaction or “upgrade” confers immunological memory to prevent tumors from returning permanently.  This synergy also can enhance tumor recognition which is important for preventing the outgrowth and spread of antigen negative lesions.  

Making CAR T More Accessible

Cell BT is meeting one of the greatest challenges facing broad CAR T availability: cost.

A highly effective therapy with an astronomical price tag is not a sustainable, scalable model. At Cell BT, we are developing a method to be used universally in combination with any CAR T therapy to reduce cytokine side effects. This will reduce the need for patient monitoring and allow treatment to take place on an outpatient basis, dramatically lowering cost.

Pipeline

We have discovered novel platforms and targets for both solid tumors and blood cancers, as well as universal approaches that promise to improve efficacy of all CAR T-cell therapies. Our lead program for hematological malignancies is being readied for Phase 1/2 clinical trial at City of Hope Cancer Center.

Therapeutic Focuses

HEMATOLOGICAL MALIGNANCIES

PROGRAM

huLym-1 DAP

CD19/huLym-1 DAP

Myeloma

STAGE

Pre-Clinical

Pre-Clinical

Pre-Clinical

PHASE

IND-enabling

SOLID TUMORS

PROGRAM

Ovarian Cancer

Deep-Seated

STAGE

Pre-Clinical

Pre-Clinical

Platforms & Applications

DAP 10/DAP 12

Co-stimulatory and signaling domains for hematological malignancies and solid tumors.

AET

Novel technology to improve the efficacy and lower the toxicity of CAR T-cell therapy of deep-seated solid tumors.

TNT & AET

Universal target for treating solid tumors.

INTRABODY METHOD

Universal method for reducing cytokine secretion by CAR T-cells, the known cause of adverse events.

EPIGENETIC
REPROGRAMMING

Treatment to induce CAR T-cell memory.

Cell BT is a collaborative team that welcomes opportunities to partner with others who can enhance the pace and outcomes of our discoveries.

Partner With Us